Description
Advanced Dual-Action GLP-1 + GIP Therapy for Weight Management and Type 2 Diabetes
Originally developed by Eli Lilly & Co. under the brand name Mounjaro®, Tirzepatide is now globally recognized for its ability to transform metabolic health by addressing both type 2 diabetes and obesity through a single, comprehensive mechanism.
How It Works
Tirzepatide mimics the body’s natural GIP and GLP-1 hormones, which are responsible for regulating glucose and appetite.
When activated together, these pathways:
Stimulate insulin secretion when blood sugar is high
Reduce glucagon release (which prevents sugar spikes)
Slow gastric emptying for longer fullness
Decrease appetite and calorie intake
This dual mechanism supports effective glycemic control and accelerated fat reduction — without the crash diets or extreme routines.
Key Benefits
Supports healthy blood sugar control
Reduces hunger and promotes satiety
Encourages steady, long-term weight loss
Once-weekly self-injection
Clinically proven and pharmaceutical grade
Concentration: 10mg/ml
Injection Type: Subcutaneous (once weekly)
Syringe Type: Built-in dial with preset delivery
Storage: Refrigerate at 2–8°C. Store up to 30 days at below 25°C.
Frequency: Inject once weekly — same day and time each week
Do not shake or freeze. Use only if solution is clear.
One pen lasts 2–12 weeks, depending on your individual dose.
Tirzepatide should be increased gradually to minimize nausea and digestive discomfort.
TIDLIRA™ Tirzepatide 10mg/ml delivers cutting-edge dual-action GLP-1 and GIP support for individuals committed to real, lasting results. With its weekly dosing convenience, precision formulation, and proven clinical performance, it’s the modern solution for weight management and type 2 diabetes control.
Reviews
There are no reviews yet.